Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events

Moneeza K Siddiqui, Gillian Smith, Pamela St Jean, Adem Y Dawed, Samira Bell, Enrique Soto-Pedre, Gwen Kennedy, Fiona Carr, Lars Wallentin, Harvey White, Colin H Macphee, Dawn Waterworth, Colin N A Palmer, Moneeza K Siddiqui, Gillian Smith, Pamela St Jean, Adem Y Dawed, Samira Bell, Enrique Soto-Pedre, Gwen Kennedy, Fiona Carr, Lars Wallentin, Harvey White, Colin H Macphee, Dawn Waterworth, Colin N A Palmer

Abstract

Aims/hypothesis: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has an independent prognostic association with major coronary events (MCE). However, no study has investigated whether type 2 diabetes status modifies the effect of Lp-PLA2 activity or inhibition on the risk of MCE. We investigate the interaction between diabetes status and Lp-PLA2 activity with risk of MCE. Subsequently, we test the resulting hypothesis that diabetes status will play a role in modifying the efficacy of an Lp-PLA2 inhibitor.

Methods: A retrospective cohort study design was utilised in two study populations. Discovery analyses were performed in the Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) cohort based in Scotland, UK. Participants were categorised by type 2 diabetes control status: poorly controlled (HbA1c ≥ 48 mmol/mol or ≥6.5%) and well-controlled (HbA1c < 48 mmol/mol or <6.5%) diabetes (n = 7420). In a secondary analysis of the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial of Lp-PLA2 inhibitor (darapladib) efficacy, 15,828 participants were stratified post hoc by type 2 diabetes diagnosis status (diabetes or no diabetes) at time of recruitment. Lp-PLA2 activity was then divided into population-specific quartiles. MCE were determined from linked medical records in GoDARTS and trial records in STABILITY. First, the interaction between diabetes control status and Lp-PLA2 activity on the outcome of MCE was explored in GoDARTS. The effect was replicated in the placebo arm of STABILITY. The effect of Lp-PLA2 on MCE was then examined in models stratified by diabetes status. This helped determine participants at higher risk. Finally, the effect of Lp-PLA2 inhibition was assessed in STABILITY in the higher risk group. Cox proportional hazards models adjusted for confounders were used to assess associations.

Results: In GoDARTS, a significant interaction between increased Lp-PLA2 activity (continuous and quartile divided) and diabetes control status was observed in the prediction of MCE (p < 0.0001). These effects were replicated in the placebo arm of STABILITY (p < 0.0001). In GoDARTS, stratified analyses showed that, among individuals with poorly controlled diabetes, the hazards of MCE for those with high (Q4) Lp-PLA2 activity was 1.19 compared with individuals with lower (Q1-3) Lp-PLA2 activity (95% CI 1.11, 1.38; p < 0.0001) and 1.35 (95% CI 1.16, 1.57; p < 0.0001) when compared with those with the lowest activity (Q1). Those in the higher risk group were identified as individuals with the highest Lp-PLA2 activity (Q4) and poorly controlled diabetes or diabetes. Based on these observations in untreated populations, we hypothesised that the Lp-PLA2 inhibitor would have more benefit in this higher risk group. In this risk group, Lp-PLA2 inhibitor use was associated with a 33% reduction in MCE compared with placebo (HR 0.67 [95% CI 0.50, 0.90]; p = 0.008). In contrast, Lp-PLA2 inhibitor showed no efficacy in individuals with low activity, regardless of diabetes status, or among those with no baseline diabetes and high Lp-PLA2 activity.

Conclusions/interpretation: These results support the hypothesis that diabetes status modifies the association between Lp-PLA2 activity and MCE. These results suggest that cardiovascular morbidity and mortality associated with Lp-PLA2 activity is especially important in patients with type 2 diabetes, particularly those with worse glycaemic control. Further investigation of the effects of Lp-PLA2 inhibition in diabetes appears warranted.

Data availability: STABILITY trial data are available from clinicaltrials.gov repository through the GlaxoSmithKline clinical study register https://ichgcp.net/clinical-trials-registry/NCT00799903 . GoDARTS datasets generated during and/or analysed during the current study are available following request to the GoDARTS Access Managements Group https://godarts.org/scientific-community/ .

Keywords: Clinical diabetes; Epidemiology; Lipids; Lipoproteins; Major coronary events; Precision medicine; Type 2 diabetes.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
GoDARTS study: demonstration of all risk groups in GoDARTS. High vs lower Lp-PLA2 activity (Q4 vs Q1–3) and diabetes control status. (a) The association between diabetes control status and high vs low Lp-PLA2 activity was significant (z = 3.80, p < 0.0001, HR 1.07 [95% CI 1.04, 1.13]). (b) Stratified effect among participants with poorly controlled diabetes. Lp-PLA2 activity in the highest quartile (Q4) compared with activity in Q1–3 was associated with 1.19 times the hazards of MCE (95% CI 1.07, 1.33) p < 0.001. (c) Stratified effect among participants with well-controlled diabetes, no significant difference in hazards of MCE for those with Lp-PLA2 activity in the highest quartile compared with lower quartiles (HR 1.04 [95% CI 0.86, 1.27]) p = 0.69. Full model in Table 2. T2D, type 2 diabetes
Fig. 2
Fig. 2
STABILITY trial: effect of Lp-PLA2 inhibitor (darapladib) therapy in the highest quartile of Lp-PLA2 activity (Q4) by diabetes status. T2D = 0 if no type 2 diabetes (T2D), T2D = 1 if type 2 diabetes; Tx, treatment. HR for Lp-PLA2 inhibition in those with type 2 diabetes 0.67 (95% CI 0.50, 0.90) p = 0.008. HR for Lp-PLA2 inhibition in those with no type 2 diabetes 0.96 (95% CI 0.74, 1.26) p = 0.78

References

    1. Packard CJ, O’Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343(16):1148–1155. doi: 10.1056/NEJM200010193431603.
    1. The Lp-PLA2 Studies Collaboration Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536–1544. doi: 10.1016/S0140-6736(10)60319-4.
    1. Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–1066. doi: 10.1038/nm.1870.
    1. Tellis C, Tselepis A. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL. Curr Pharm Des. 2014;20(40):6256–6269. doi: 10.2174/1381612820666140622200916.
    1. Jackisch L, Kumsaiyai W, Moore JD, et al. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids. Diabetologia. 2018;61(5):1155–1166. doi: 10.1007/s00125-018-4558-6.
    1. The STABILITY Investigators et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–1711. doi: 10.1056/NEJMoa1315878.
    1. O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006–1015. doi: 10.1001/jama.2014.11061.
    1. Siddiqui MK, Kennedy G, Carr F, et al. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia. 2018;61(6):1344–1353. doi: 10.1007/s00125-018-4601-7.
    1. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis. 1993;102(1):63–67. doi: 10.1016/0021-9150(93)90084-8.
    1. Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 1984;33(2):130–134. doi: 10.2337/diab.33.2.130.
    1. He S, Chousterman BG, Fenn A, et al. Lp-PLA2 antagonizes left ventricular healing after myocardial infarction by impairing the appearance of reparative macrophages. Circ Heart Fail. 2015;8(5):980–987. doi: 10.1161/CIRCHEARTFAILURE.115.002334.
    1. Hébert HL, Shepherd B, Milburn K, et al. Cohort profile: genetics of diabetes audit and research in Tayside Scotland (GoDARTS) Int J Epidemiol. 2018;47(2):380–381j. doi: 10.1093/ije/dyx140.
    1. Wallentin L, Held C, Armstrong PW et al (2016) Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. J Am Heart Assoc 5(6):e00347. 10.1161/JAHA.116.003407
    1. Zhuo S, Wolfert RL, Yuan C. Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A2 explain the discordance in results between the two assay methods. Clin Biochem. 2017;50(18):1209–1215. doi: 10.1016/j.clinbiochem.2017.08.019.
    1. Topbas C, Swick A, Razavi M, Anderson NL, Pearson TW, Bystrom C. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and Activity assays. Clin Chem. 2018;64(4):697–704. doi: 10.1373/clinchem.2017.279752.
    1. WHO . Classification of diabetes mellitus. Geneva: World Health Organization; 2019.
    1. Dorresteijn JAN, Visseren FLJ, Wassink AMJ, et al. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013;99(12):866–872. doi: 10.1136/heartjnl-2013-303640.
    1. Kassambara A, Kosinski M, Biecek P (2019) ggsurvplot: Drawing Survival Curves. Available from: . Accessed: 1 July 2020
    1. Aronson D, Rayfield EJ, Stamler J, et al. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care. 1993;16(Supplement_2):72–78. doi: 10.2337/diacare.16.2.72.
    1. Tanaka A, Miyauchi K, Mokuno H, Daida H. Pathogenesis of atherosclerosis in diabetes mellitus. Respiration and Circulation. 2005;53(3):229–235.
    1. Webb NR. Getting to the core of atherosclerosis. Nat Med. 2008;14:1015. doi: 10.1038/nm1008-1015.
    1. Grallert H, Dupuis J, Bis JC, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012;33(2):238–251. doi: 10.1093/eurheartj/ehr372.
    1. Chu AY, Guilianini F, Grallert H, et al. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Circ Cardiovasc Genet. 2012;5(6):676–685. doi: 10.1161/CIRCGENETICS.112.963314.
    1. Cosentino F, Grant PJ, Aboyans V et al (2019) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 255–323. 10.1093/eurheartj/ehz486
    1. International Diabetes Federation (2017) IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care International Diabetes Federation. Available from: . Accessed: 1 June 2019
    1. American Diabetes Association Screening for type 2 diabetes. Diabetes Care. 2004;27(suppl 1):s11–s14. doi: 10.2337/diacare.27.2007.S11.
    1. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006;12(Suppl 1):6–12. doi: 10.4158/EP.12.S1.6.
    1. Monnier L, Colette C. Target for glycemic control: concentrating on glucose. Diabetes Care. 2009;32(Suppl 2):S199–S204. doi: 10.2337/dc09-s310.
    1. Ceriello A, Colagiuri S. International diabetes federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med. 2008;25(10):1151–1156. doi: 10.1111/j.1464-5491.2008.02565.x.
    1. NHS (2018) Hyperglycaemia (high blood sugar). Available from: . Accessed: 1 June 2019
    1. Hu G, Liu D, Tong H, Huang W, Hu Y, Huang Y. Lipoprotein-associated phospholipase A2 activity and mass as independent risk factor of stroke: a Meta-analysis. Biomed Res Int. 2019;2019:8642784. doi: 10.1155/2019/8642784.
    1. Millwood IY, Bennett DA, Walters RG, et al. A phenome-wide association study of a lipoprotein-associated phospholipase a 2 loss-of-function variant in 90 000 Chinese adults. Int J Epidemiol. 2016;45(5):1588–1599. doi: 10.1093/ije/dyw087.
    1. Wang Q, Hao Y, Mo X, et al. PLA2G7 gene polymorphisms and coronary heart disease risk: a meta-analysis. Thromb Res. 2010;126(6):498–503. doi: 10.1016/j.thromres.2010.09.009.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera